Author: Ravi Shankar

• 2026 operating profit expected to reach CHF 115 million (previously CHF 70 million) driven by higher than expected Cresemba and Zevtera-related revenue of CHF 250 million (previously CHF 210 million)
• Cumulative cash flow target for “Agenda 2030” raised to CHF 650 million (previously CHF 600 million)
• Updates on design of late-stage clinical program for ceftibuten-ledaborbactam and progress of fosmanogepix phase 3 studies
• Capital Markets Day on October 28, 2026

Ad hoc announcement pursuant to Art. 53 LR

Allschwil, Switzerland, October 27, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it is raising its financial guidance for the full year 2026 and the cumulative cash flow target for 2026-2030 from its commercialized products within the strategic initiative, “Agenda 2030”. The company also provided updates on the progress of its late-stage clinical programs for ceftibuten-ledaborbactam and fosmanogepix, ahead of its Capital Markets Day taking place tomorrow in Zurich.

David Veitch, Chief Executive Officer, said: “The sustained momentum of our commercial business reinforces the financial foundations of our “Agenda 2030” and enhances our capacity to continue to invest in future growth. By 2030, we aim to establish a diversified business with four commercialized products and an industry-leading anti-infectives R&D pipeline. We look forward to engaging with investors, analysts and media at tomorrow`s Capital Markets Day in Zurich as we outline the next phase of Basilea’s growth.”

Adesh Kaul, Chief Financial Officer, added: “Cresemba’s continued strong growth underscores the quality and durability of our commercial franchise. The significant increase in expected milestone income allows us to raise our full-year 2026 guidance for Cresemba and Zevtera-related income to CHF 250 million, 19% above our previous guidance. Given Cresemba’s sustained momentum, we are also increasing our “Agenda 2030” target for cumulative cash flow from Cresemba and Zevtera from CHF 600 million to CHF 650 million. This enhanced outlook strengthens our ability to fund future growth initiatives.”

Regarding the update of the late-stage clinical program for ceftibuten-ledaborbactam, Dr. Marc Engelhardt, Chief Medical Officer, stated: “Our recent consultations with the FDA and EMA have provided greater clarity on a streamlined clinical development pathway for ceftibuten-ledaborbactam and the data package required to support our targeted positioning: aiming for a broad, unrestricted use for patients with complicated urinary tract infections. As a result, we are now planning a phase 2/3 study under one study umbrella, without a separate confirmatory phase 3 study, and remain on track to initiate this study mid-2027. This approach will require fewer patients than running a program with two separate phase 3 studies and offers the opportunity for a data readout from the phase 2 part as early as end-2028. We are currently focused on completing the remaining preparatory work, including; finalizing the phase 2/3 study protocol, completing the ongoing phase 1 study providing further tolerability and safety data¹, complementary PK/PD analysis and securing clinical trial material.”

On the progress of its late-stage clinical program for fosmanogepix^{2, 3}, he added: “Our global phase 3 program for fosmanogepix progresses toward data readouts in mid-2028. We have successfully completed recruitment into the salvage therapy cohort of the invasive mold infection study, marking another important program milestone, while recruitment continues in the mold study’s other cohorts and in the invasive candidiasis study. Our goal is to maximize the potential of fosmanogepix by pursuing the broadest possible label at launch. We therefore plan to include results from both phase 3 studies in our initial regulatory filings.”

Increased full-year 2026 revenue guidance and raised cumulative cash flow target for “Agenda 2030”

Basilea provides the following updated guidance for the full year (FY) 2026 versus FY 2025:

(in CHF million / percent)	FY 2026 updated guidance	FY 2026 previous guidance	FY 2025 Actuals
Cresemba and Zevtera-related revenue	~250	~210	194.4
Total revenue	~310 (~33% increase)	~15% increase	232.4
Research & development expenses	~125 (~18% increase)	~20% increase	105.9
Operating profit	~115 (~123% increase)	~40% increase	51.5

• Cresemba and Zevtera-related revenue is now expected to increase to CHF ~250 million (versus CHF ~210 million previous guidance) with a cash contribution of CHF ~215 million (versus CHF ~180 million previous guidance). Milestone payments are now expected to reach CHF ~65 million (versus CHF ~35 million previous guidance).
• Within “Agenda 2030”, this results in an expected increase of cumulative cash flow from Cresemba and Zevtera from 2026 to 2030 to CHF 650 million (previously: CHF 600 million).

Basilea conducts Capital Markets Day tomorrow in Zurich, October 28, 2026

The event will provide the audience with a comprehensive update on the company’s strategic direction and value drivers and will include presentations from senior management and external experts. For further details on the agenda and registration, please visit https://basilea-cmd.com/#E4A948

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Fosmanogepix and ceftibuten-ledaborbactam

These projects have been funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA). Fosmanogepix is funded under OT number: 75A50124C00033 and ceftibuten-ledaborbactam under contract 75A50123C00050. The contracts and federal funding are not an endorsement of the study results, product, or company.

For further information, please contact:

Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland
Phone	+41 61 606 1102
E-mail	media_relations@basilea.com investor_relations@basilea.com

This ad hoc announcement can be downloaded from www.basilea.com.

References

1. ClinicalTrials.gov identifier: NCT06733675
2. FAST-IC (Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis: ClinicalTrials.gov identifier: NCT05421858
3. FORWARD-IM (FOsmanogepix study Run Worldwide as Antifungal treatment in Resistant Disease caused by Invasive Molds): ClinicalTrials.gov identifier: NCT06925321

Attachment

• Press release (PDF)

Ad hoc announcement pursuant to Art. 53 LR

Third quarter

• Q3 net sales grew +4% (cc^¹, +4% USD), with core operating income^¹ +10% (cc, +11% USD)
  • Sales growth driven by priority brands including Kisqali (+37% cc), Kesimpta (+22% cc), Scemblix (+67% cc), Leqvio (+63% cc) and Cosentyx (+9% cc)
  • Core operating income margin^¹ was 41.6%, +2 percentage points (cc)
• Q3 operating income declined -61% (cc, -59% USD) mainly due to a partial impairment of the del-desiran asset; net income down -71% (cc, -70% USD)
• Q3 core EPS^¹ grew +8% (cc, +9% USD) to USD 2.46
• Q3 free cash flow^¹ was USD 5.1 billion (-18% USD)
• 9 months net sales (0% cc, +2% USD) and core operating income (-2% cc, -1% USD) broadly in line with PY
• Q3 selected innovation milestones:
  • Remibrutinib positive PhIII REMODEL-1 and -2 results in RMS
  • Rhapsido FDA approval in most prevalent form of CIndU
  • Pluvicto FDA and CN approvals in mAPMN/S prostate cancer
  • Pelabresib EU submission completed in MF
  • Del-zota FDA priority review granted for DMD44
• Full-year 2026 guidance²  raised for core operating income
  • Net sales expected to grow low single-digit (unchanged)
  • Core operating income expected to be in line to grow low single-digit (from decline low single-digit)

Basel, October 27, 2026 – Commenting on Q3 2026 results, Vas Narasimhan, CEO of Novartis, said:
“Novartis delivered solid sales growth in Q3, as priority brands and launches more than offset generic erosion, demonstrating the replacement power of the business. Combined with productivity efforts, this drove strong bottom-line performance and allowed us to upgrade our full-year guidance. At the same time, we continued to advance our pipeline, with positive Phase III results for remibrutinib in RMS, label expansions for Rhapsido and Pluvicto in the US, and the first submission for pelabresib in the EU. While the del-desiran readout in DM1 was not what we had hoped, we saw evidence of clinical activity in the data and are working through the development path for this medicine. Importantly, our programs in FSHD and DMD continue to progress well. With continued momentum across the business and pipeline, we remain well on track to deliver our mid- and long-term outlook.”

Key figures
	Q3 2026	Q3 2025	% change			9M 2026	9M 2025	% change
	USD m3	USD m3	USD	cc		USD m3	USD m3	USD	cc
Net sales	14 522	13 909	4	4		42 043	41 196	2	0
Operating income	1 843	4 501	-59	-61		10 828	14 028	-23	-24
Net income	1 196	3 930	-70	-71		7 609	11 563	-34	-35
EPS (USD)	0.63	2.04	-69	-70		4.01	5.94	-32	-33
Free cash flow	5 111	6 217	-18			14 002	15 941	-12
Core operating income	6 036	5 460	11	10		16 873	16 960	-1	-2
Core net income	4 655	4 330	8	6		13 027	13 522	-4	-5
Core EPS (USD)	2.46	2.25	9	8		6.85	6.94	-1	-3

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.    2. Please see detailed guidance assumptions on page 7.    3. USD millions unless indicated otherwise.

Strategy

Our focus

Novartis is a “pure-play” innovative medicines company. We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential. In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale. Geographically, we are focused on growing in our priority geographies – the US, China, Germany and Japan.

Our priorities

1. Accelerate growth: Renewed attention to deliver high-value medicines (NMEs) and focus on launch excellence, with a rich pipeline across our core therapeutic areas.
2. Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with substantial cash generation and a strong capital structure supporting continued flexibility.
3. Strengthen foundations: Unleashing the power of our people, scaling data science and technology, and continuing to build trust with society.

Financials

Third quarter

Net sales were USD 14.5 billion (+4%, +4% cc), with volume growth contributing 14 percentage points, partly offset by 9 percentage points from generic competition. Pricing had a negative impact of 1 percentage point, and currency had no impact.

Operating income was USD 1.8 billion (-59%, -61% cc), declining mainly due to higher R&D expenses, including a USD 1.9 billion partial impairment charge of the del-desiran IPR&D asset, and higher other expense, partly offset by higher net sales.

Net income was USD 1.2 billion (-70%, -71% cc), declining mainly due to lower operating income and higher interest expense. EPS was USD 0.63 (-69%, -70% cc).

Core operating income was USD 6.0 billion (+11%, +10% cc), mainly driven by higher net sales. Core operating income margin was 41.6% of net sales, increasing 2.3 percentage points (2.0 percentage points in cc).

Core net income was USD 4.7 billion (+8%, +6% cc), driven by higher core operating income, partly offset by higher interest expense. Core EPS was USD 2.46 (+9%, +8% cc), benefiting from the lower weighted average number of shares outstanding.

Free cash flow amounted to USD 5.1 billion (-18%), declining due to lower net cash flows from operating activities.

Nine months

Net sales were USD 42.0 billion (+2%, 0% cc), with volume growth contributing 14 percentage points, partly offset by 12 percentage points from generic competition. Pricing had a negative impact of 2 percentage points, and currency had a positive impact of 2 percentage points.

Operating income was USD 10.8 billion (-23%, -24% cc), declining mainly due to higher R&D expenses, including a USD 1.9 billion partial impairment charge of the del-desiran IPR&D asset, and higher other expense.

Net income was USD 7.6 billion (-34%, -35% cc), mainly due to lower operating income, higher interest expense and higher income taxes. EPS was USD 4.01 (-32%, -33% cc).

Core operating income was USD 16.9 billion (-1%, -2% cc), declining mainly due to higher R&D expenses and higher other expense, partly offset by lower SG&A expenses. Core operating income margin was 40.1% of net sales, decreasing 1.1 percentage points (0.8 percentage points in cc).

Core net income was USD 13.0 billion (-4%, -5% cc), mainly due to lower core operating income and higher interest expense. Core EPS was USD 6.85 (-1%, -3% cc), benefiting from the lower weighted average number of shares outstanding.

Free cash flow amounted to USD 14.0 billion (-12%), declining due to lower net cash flows from operating activities.

Q3 priority brands

Underpinning our financial results in the quarter is a continued focus on key growth drivers (ranked in order of contribution to Q3 growth) including:

Kisqali	(USD 1 821 million, +37% cc) continued to grow strongly across all regions, with market share growth in early breast cancer and leadership in metastatic breast cancer.
Kesimpta	(USD 1 484 million, +22% cc) sales showed continued strong momentum globally, driven by increased demand and broad access.
Scemblix	(USD 593 million, +67% cc) sales grew across all regions, with continued strong momentum in the early-line setting in the US, Japan and Germany.
Leqvio	(USD 506 million, +63% cc) sales grew across all regions, with continued uptake in China following NRDL inclusion.
Cosentyx	(USD 1 857 million, +9% cc) sales grew in most markets, driven by the HS and SpA indications. US growth benefited from prior-year revenue deduction adjustments.
Pluvicto	(USD 674 million, +20% cc) sales showed continued strong demand driven by the mAPMR¹ setting, with US and China approvals in mAPMN/S²  in Q3, and ongoing access expansion ex-US.
Zolgensma Group	(USD 404 million, +35% cc) sales grew strongly, reflecting continued launch momentum from Itvisma in the US, Japan and other ex-US countries.
Rhapsido	(USD 101 million) continued to show strong launch uptake in the US, supported by sustained prescription growth and a free drug program facilitating patient access. Ex-US, sales were mainly driven by early launch uptake in Germany and China.
Fabhalta	(USD 237 million, +60% cc) sales grew, with expansion in PNH and renal indications.

¹ Metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), also known as metastatic castration resistant prostate cancer (mCRPC).
^²  Metastatic androgen pathway modulation-naïve or sensitive prostate cancer (mAPMN/S), also known as metastatic hormone-sensitive prostate cancer (mHSPC).

Net sales of the top 20 brands in the third quarter and nine months

	Q3 2026	% change		9M 2026	% change
	USD m	USD	cc	USD m	USD	cc
Cosentyx	1 857	9	9	5 247	8	6
Kisqali	1 821	37	37	5 032	45	44
Kesimpta	1 484	21	22	4 072	27	26
Entresto	1 165	-38	-38	3 651	-44	-45
Pluvicto	674	20	20	1 967	42	41
Jakavi	564	5	5	1 697	9	6
Tafinlar + Mekinist	570	4	4	1 644	-2	-4
Ilaris	591	25	26	1 616	18	17
Scemblix	593	66	67	1 588	78	78
Leqvio	506	64	63	1 438	67	63
ZolgensmaGroup	404	34	35	1 071	16	13
Xolair	331	-25	-25	1 061	-21	-23
SandostatinGroup	311	3	3	900	-2	-4
Lutathera	219	3	3	655	7	6
Fabhalta	237	59	60	631	80	79
ExforgeGroup	183	4	1	577	6	2
Promacta/Revolade	142	-61	-61	505	-64	-65
DiovanGroup	137	-4	-6	447	0	-3
Tasigna	141	-36	-37	438	-53	-54
Piqray/Vijoice	122	36	37	326	8	8
Top 20 brands total	12 052	7	7	34 563	3	1

R&D update – key developments from the third quarter

New approvals

Rhapsido (remibrutinib)	In October, FDA approved Rhapsido as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines, expanding its use beyond chronic spontaneous urticaria (CSU) into chronic inducible urticaria (CIndU). Novartis plans to submit the full RemIND dataset to health authorities globally.
Pluvicto (lutetium Lu177 vipivotide tetraxetan)	FDA and China’s NMPA approved Pluvicto in combination with an androgen receptor pathway inhibitor (ARPI) for patients with PSMA+ metastatic androgen pathway modulation-naive/sensitive (mAPMN/S) prostate cancer¹. Pluvicto is now approved across all stages of PSMA+ metastatic prostate cancer.
Fabhalta (iptacopan)	Japan’s MHLW approved Fabhalta for the treatment of IgA nephropathy (IgAN), making it the first approved treatment for this indication in Japan.   Additionally, FDA granted traditional approval of Fabhalta in IgAN.

¹  Also known as metastatic hormone-sensitive prostate cancer (mHSPC).

Regulatory updates

Cosentyx (secukinumab)	CHMP adopted a positive opinion recommending approval for Cosentyx in polymyalgia rheumatica (PMR), based on positive Phase III REPLENISH data. If approved, Cosentyx will be the first IL-17A inhibitor approved in Europe for PMR.
DAK539 (pelabresib)	Regulatory submission for pelabresib in myelofibrosis was completed in the EU, based on the positive Phase III MANIFEST-2 study, which showed deep and durable disease control, with a safety profile comparable to ruxolitinib alone, including numerically fewer deaths and disease progressions in the pelabresib arm.
KPE179 (del-zota)	Del-zota was granted priority review by FDA for people living with Duchenne muscular dystrophy who have a genetic variant that may be amenable to exon 44 skipping (DMD44). Del-zota previously received FDA Breakthrough Therapy designation.
Leqvio (inclisiran)	FDA updated the Leqvio label to include language recognizing that lowering LDL-C reduces the risk of major adverse cardiovascular events (MACE) in adults at increased cardiovascular risk. This update reflects established evidence from statins and monoclonal antibody PCSK9 inhibitors, supporting LDL-C reduction as a key component of cardiovascular risk management.
Vanrafia (atrasentan)	Regulatory submissions for Vanrafia in IgAN were completed in Japan and China.
KLU156 (ganaplacide + lumefantrine)	Regulatory submission for KLU156 in uncomplicated malaria was completed in the US and received priority review.

Results from ongoing trials and other highlights

LOU064 (remibrutinib)	Positive results from the Phase III REMODEL-1 and -2 trials showed oral remibrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), significantly reducing annualized relapse rate (ARR) versus teriflunomide. Remibrutinib also showed superiority on all key secondary endpoints, including MRI lesion reduction, and a clinically meaningful delay in disability progression. The safety profile was favorable and consistent with remibrutinib in CSU, with no liver safety signal. Data were presented at MSToronto2026 in October.
EWF980 (del-desiran)	In the Phase III HARBOR study, del-desiran did not meet its primary endpoint of video hand opening time (vHOT) versus placebo in myotonic dystrophy type 1 (DM1). Evidence of clinical activity was observed in secondary endpoints and exploratory analyses. Novartis is evaluating the full HARBOR dataset and will engage with health authorities to determine the most appropriate development path. Data will be presented at an upcoming medical congress.
TQJ230 (pelacarsen)	In the Phase III HORIZON trial, pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events versus placebo in patients with elevated Lp(a) and established cardiovascular disease (CVD), despite reducing Lp(a) levels in this study population. The findings provide important new evidence on the relationship between Lp(a) lowering and cardiovascular outcomes and may help inform future approaches to cardiovascular risk management. Data will be presented at an upcoming medical congress.
Kisqali (ribociclib)	The six-year follow-up analysis of the Phase III NATALEE trial showed a clinically meaningful overall survival (OS) benefit with Kisqali plus endocrine therapy (ET) versus ET alone in the broadest HR+/HER2- early breast cancer (eBC) population at high risk of recurrence, reducing the risk of death by nearly 20%. Patients had been off Kisqali treatment for a median of 38 months, with clinical benefit continuing to deepen after treatment completion. The safety profile remained consistent with previous analyses. Data were presented at ESMO 2026.
LOU064 (remibrutinib)	Novartis has discontinued the Phase III study of remibrutinib in generalized myasthenia gravis (gMG) following a futility analysis, which indicated the treatment was unlikely to meet its efficacy objectives. No safety concerns were identified, and there is no impact on remibrutinib studies in other indications.
Selected transactions	Novartis completed the acquisition of Myricx Bio, strengthening the oncology pipeline with a new class of antibody-drug conjugates (ADCs), including two lead assets targeting B7-H3 and HER2, as well as a broader payload platform with potential impact across multiple solid tumor settings.   Novartis exercised its exclusive option to acquire full global rights to Sironax’s proprietary Brain Delivery Module (BDM) platform, a next-generation blood-brain barrier crossing technology with the potential to transform the treatment of central nervous system diseases.   Novartis entered into an exclusive global licensing agreement with BoomRay Pharmaceuticals for an undisclosed preclinical radioligand therapy asset, further strengthening its radioligand therapy portfolio.   In October, Novartis entered into a strategic licensing and option agreement with Abogen Biosciences to advance RNA-encoded therapeutics, including an exclusive worldwide license to ABO2203, a novel mRNA-encoded CD19xCD3 T-cell engager with the potential to transform the treatment landscape for autoimmune diseases. The transaction is subject to the completion of customary closing conditions.

Capital structure and net debt

Retaining a good balance between investment in the business, a strong capital structure, and attractive shareholder returns remains a priority.

During the first nine months of 2026, Novartis repurchased 30.9 million shares for USD 4.7 billion on the SIX Swiss Exchange second trading line. These repurchases included 18.8 million shares (USD 2.8 billion) under the up-to USD 10 billion share buyback announced in July 2025 (with up to USD 4.9 billion still to be executed). In addition, 12.1 million shares (USD 1.8 billion) were repurchased to mitigate the anticipated full-year dilution related to participation plans of employees. Further, 2.0 million shares (USD 0.3 billion) were repurchased from employees. During the same period, USD 0.9 billion of equity-based compensation plan expenses were recognized to equity and 13.3 million shares were delivered to employees related to equity-based compensation plans from prior years. As a result, the total number of shares outstanding decreased by 19.6 million compared with December 31, 2025. These treasury share transactions resulted in an equity decrease of USD 4.1 billion and a cash outflow of USD 4.8 billion.

Net debt increased to USD 37.4 billion at September 30, 2026, compared with USD 21.9 billion at December 31, 2025. The increase was mainly due to the free cash flow of USD 14.0 billion being more than offset by the net cash outflow for M&A, intangible assets transactions and other acquisitions of USD 16.7 billion, the USD 9.1 billion annual dividend payment and cash outflows for treasury share transactions of USD 4.8 billion.

As of Q3 2026, the long-term credit rating for the company is Aa3 with Moody’s Ratings and AA- with S&P Global Ratings.

2026 outlook

Barring unforeseen events; growth vs. prior year in cc
Net sales	Expected to grow low single-digit
Core operating income	Expected to be in line to grow low single-digit (from decline low single-digit)

Foreign exchange impact

If late-October exchange rates prevail for the remainder of 2026, the foreign exchange impact for the year would be positive 1 percentage point on net sales and positive 1 percentage point on core operating income. The estimated impact of exchange rates on our results is provided monthly on our website.

2027 Annual General Meeting

Nomination for election to the Board of Directors

The Novartis Board of Directors announced today that it is nominating Rajesh Jha for election to the Board. During a 36-year career at Microsoft, Mr. Jha held a series of senior leadership roles across software engineering, productivity platforms and enterprise technologies, and served on the company’s Senior Leadership Team from 2016 until his retirement. Most recently, he served as Executive Vice President, Experiences + Devices, where he led the product teams for Microsoft 365, Office, Teams, Windows + Devices, and Dynamics, and played a key role in the integration of artificial intelligence across Microsoft’s product portfolio. His extensive experience in technology, AI and large-scale digital platforms would add significantly to the Novartis Board of Directors.

Key figures¹ 

	Q3 2026	Q3 2025	% change			9M 2026	9M 2025	% change
	USD m²	USD m²	USD	cc		USD m²	USD m²	USD	cc
Net sales	14 522	13 909	4	4		42 043	41 196	2	0
Operating income	1 843	4 501	-59	-61		10 828	14 028	-23	-24
As a % of sales	12.7	32.4				25.8	34.1
Net income	1 196	3 930	-70	-71		7 609	11 563	-34	-35
EPS (USD)	0.63	2.04	-69	-70		4.01	5.94	-32	-33
Net cash flows from operating activities	5 503	6 571	-16			15 061	16 880	-11
Non-IFRS measures
Free cash flow	5 111	6 217	-18			14 002	15 941	-12
Core operating income	6 036	5 460	11	10		16 873	16 960	-1	-2
As a % of sales	41.6	39.3				40.1	41.2
Core net income	4 655	4 330	8	6		13 027	13 522	-4	-5
Core EPS (USD)	2.46	2.25	9	8		6.85	6.94	-1	-3

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.     2. USD millions unless indicated otherwise.

Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below:
https://www.novartis.com/sites/novartis_com/files/q3-2026-interim-financial-report-en.pdf

Disclaimer
This communication contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “expected,” “anticipated,” “can,” “will,” “continue,” “ongoing,” “growth,” “launch,” “expanding,” “deliver,” “accelerate,” “guidance,” “outlook,” “priority,” “potential,” “momentum,” “on track,” “pipeline,” “evidence,” “progress,” “emerging,” or similar expressions, or by express or implied discussions regarding: potential new products, potential new indications for existing products, potential product launches or potential future revenues from any such products; or results of ongoing clinical trials; potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this communication will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the expected benefits or synergies from the transactions described in this communication will be achieved in the expected timeframe, or at all. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of key products, commercial priorities and strategy; the research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; the implementation of our new IT projects and systems; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this communication; safety, quality, data integrity, or manufacturing issues; our performance on and ability to comply with environmental, social and governance measures and requirements; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

All product names appearing in italics are trademarks owned by or licensed to Novartis.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

Novartis will conduct a conference call with investors to discuss this news release today at 13:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Novartis website. A replay will be available after the live webcast by visiting https://www.novartis.com/investors/event-calendar.

Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below. Additional information is provided on our business and pipeline of selected compounds in late-stage development. A copy of today’s earnings call presentation can be found at https://www.novartis.com/investors/event-calendar.

Important dates
November 18-19, 2026	Meet Novartis Management 2026 (London, UK)
February 3, 2027	Fourth quarter & full year 2026 results
March 5, 2027	Annual General Meeting

# # #

Novartis Media Relations E-mail: media.relations@novartis.com
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

Please find full media release in English attached and on the following link:
Media release (PDF)

Further language versions are available through the following links:

German version is available through the following link:
Medienmitteilung (PDF)

• Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations
• RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025, reflecting demand stabilization and seasonal inventory increase
• Joenja® (leniolisib) revenue increased by 58% to US$23.8 million, compared to third quarter 2025, reflecting strong U.S. and international demand
• Tightened 2026 total revenue guidance to US$380 million – US$390 million from prior US$375 million – US$395 million
• Operating profit increased by 89% to US$29.9 million, compared to third quarter 2025
• Generated US$32.4 million in cash flow from operations in the quarter and US$24.7 million year to date, increasing cash position to US$190.9 million
• Strong progress on Joenja expansion including U.S. pediatric label and launches in Germany and Japan
• Announced positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation and Phase II topline data in broader CVID patient population expected in November 2026
• Pharming to host a conference call today at 13:30 CET (8:30 am EDT)

Leiden, the Netherlands, October 27, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, presents its preliminary (unaudited) financial report for the three months ended September 30, 2026.

Interim Co-Chief Executive Officer Kenneth Lynard commented: “This was a quarter of execution and delivery for Pharming. We set three near-term goals – stabilizing and returning RUCONEST to revenue growth, expanding Joenja (leniolisib)’s reach, and generating Phase II data for leniolisib beyond APDS. We made strong progress on all three in the third quarter, and momentum continues into the fourth quarter. RUCONEST quarterly revenue rose 14% year-over-year to $93.8 million, supported by stabilized U.S. demand with the strongest retention in the high-burden patient segment, and continued new patient and prescribers additions. Joenja revenue grew 58% to $23.8 million with launches in Germany and Japan, higher U.S. uptake, and approval in the U.S. of new doses for children aged 4 to 11 above 27 kg with shipments commencing after quarter end. That performance translated into 21% revenue growth exceeding market expectations, an 89% increase in operating profit, and strong operating cash flow, highlighting our flexibility to invest in our priorities while staying disciplined on capital allocation.

Interim Co-Chief Executive Officer Leverne Marsh added: We are particularly encouraged by the recent positive Phase II results for leniolisib in genetically identifiable primary immunodeficiencies, which support the role of the PI3Kδ pathway in driving immune dysregulation beyond APDS. We look forward to reporting additional data in CVID in November. Together, results from both trials will inform the path toward a potential registrational study in the broader and larger CVID population. If supported by the data, this could represent a significant opportunity for leniolisib, building on the commercial capabilities we have established with Joenja to reach more patients and realize our long-term growth ambition.”

Third quarter highlights

Commercialized assets
RUCONEST marketed for the treatment of acute HAE attacks

RUCONEST revenue in the third quarter of 2026 was US$93.8 million, a 14% increase compared to the third quarter of 2025 and a 30% increase compared to the second quarter of 2026. Revenue for the first nine months of 2026 was US$224.5 million, a 3% decrease compared to the same period in 2025.

RUCONEST revenue in the current quarter compared to the third quarter of 2025 reflects stabilization and continued recovery of U.S. market demand, early seasonal increase in channel inventory at a single U.S. specialty pharmacy customer following significant drawdowns earlier in the year, and the completion of the planned withdrawal from non-U.S. markets.

The overwhelming majority of RUCONEST patients remain on therapy with the active patient base over 90% of year ago levels, with strongest retention in the high-burden patient segment. We continued to add new patients and prescribers, highlighting RUCONEST’s durable market position in high-burden HAE.

Joenja (leniolisib) marketed for the treatment of APDS

Joenja revenue increased to US$23.8 million in the third quarter of 2026, a 58% increase compared to the third quarter of 2025. Revenue for the first nine months of 2026 was US$55.7 million, a 45% increase compared to the same period in 2025.

Year-over-year revenue growth in the current quarter was driven by continued strong growth in the number of U.S. patients on paid therapy, significantly increased international demand – including from launches in Germany and Japan during the quarter and continued penetration in the U.K. – with temporary benefit from ordering patterns in other international markets.

The U.S. market contributed 67% of third quarter revenue, while international contributed 33%.

As of September 30, 2026, 136 patients were on paid therapy in the U.S., representing a 17% increase from the 116 patients at the end of the third quarter of 2025 and an increase of 4 patients during the quarter. Shipments of newly approved Joenja doses for children aged 4 to 11 years in the U.S. commenced in October, following the end of the quarter.

As of September 30, 2026, 75 patients were on paid therapy in international markets – 30 in launch markets and 45 on paid access programs in other international markets.

APDS patient finding

As of September 30, 2026, we have identified 1,056 diagnosed activated PI3Kδ syndrome (APDS) patients of all ages globally, including 304 patients in the U.S. and 390 in core markets outside of the U.S.

Joenja (leniolisib) development
Leniolisib for APDS

As of September 30, 2026, there are 136 APDS patients in either a leniolisib Expanded Access Program (compassionate use) or an ongoing clinical study.

Pediatric label expansion

On September 11, 2026, we announced that the U.S. Food and Drug Administration (FDA) had approved our supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja as a treatment for children aged 4 to 11 years weighing at least 27 kg with APDS.

On July 30, 2026, we submitted a separate sNDA seeking approval of lower Joenja doses for pediatric APDS patients aged 4 to 11 years who weigh 13 kg to 27 kg. On September 28, 2026, we announced that the FDA had accepted this sNDA and granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027.

Japan

On August 13, 2026, we announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 years and older, following its inclusion on the Japan National Health Insurance (NHI) drug price list. With this launch, Japan became the first market where Joenja was commercially available for children aged 4 to 11.

Leniolisib for additional primary immunodeficiencies (PIDs)

Two Phase II clinical trials are evaluating leniolisib for additional primary immunodeficiencies (PIDs) with immune dysregulation, including genetically identifiable PIDs linked to altered PI3Kδ signaling and common variable immunodeficiency (CVID), which represent substantially larger patient populations than APDS. The PI3Kδ pathway is seen as a key driver of immune dysregulation in many PIDs, and we are working towards a single registrational Phase III trial in the broader CVID indication, incorporating patient populations from both studies.

On October 14, 2026, we presented positive topline data from our Phase II trial of leniolisib in genetically identifiable PIDs with immune dysregulation at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID). This is the first clinical data for leniolisib in broader PIDs beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation. The trial enrolled 13 participants, nine of whom also had a CVID diagnosis. All participants who completed the study elected to continue receiving treatment in a long-term extension study.

The presentation highlighted leniolisib’s favorable safety and tolerability profile, as well as clinical improvements across measures of immune dysregulation. Clinical results included improvements in lymphoproliferative disease, with mean 26.4% spleen volume reduction (SVR) including reductions in nearly all evaluable participants, and reductions in the size of index lesions. Positive trends in lung and liver disease markers were also particularly noteworthy. The safety observations were consistent with the known safety profile of leniolisib, with infections as the most common events observed in study subjects, and no new safety signals identified. Notably, all 12 participants who completed the study elected to enroll in the three-year extension study.

Pharming expects to report Phase II results for leniolisib in CVID patients with immune dysregulation, with or without an identified genetic cause, in November 2026.

The estimated prevalence rate is approximately 7.5 patients per million for genetically identifiable PIDs and approximately 39 patients per million for CVID with immune dysregulation, including overlap between the genetic PID and CVID populations, which are substantially larger than the approximately 1.5 patients per million for APDS.

Napazimone (KL1333) for mitochondrial DNA-driven primary mitochondrial disease

Napazimone (KL1333) is being evaluated in the pivotal FALCON clinical trial in adult patients with mtDNA-driven mitochondrial disease, and has the potential to become the first standard of care in this setting.

Over 50 clinical sites in the trial are actively recruiting, with significant expansion achieved in the U.S. We expect approximately 145 of the planned 180 subjects to be enrolled in FALCON by the end of 2026. We now expect enrollment to be completed in the first half of 2027. Topline results from the pivotal FALCON study are expected approximately one year after the completion of enrollment.

Organizational updates

On September 29, 2026, we announced that the Board of Directors and Fabrice Chouraqui had mutually agreed that Mr. Chouraqui would step down as Chief Executive Officer and Executive Director, with immediate effect. To ensure continuity of leadership, the Board of Directors appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs.

Pharming’s strategy, pipeline and commitment to patients remain unchanged. Focus remains on executing the strategic priorities and advancing the next phase of growth.
Financial Summary

Consolidated Statement of Income	3Q 2026	3Q 2025	9M 2026	9M 2025
Amounts in US$m except per share data
Total Revenues	117.6	97.3	280.2	269.6
Cost of sales	(15.4)	(7.1)	(36.6)	(24.4)
Gross profit	102.2	90.2	243.7	245.2
Other income	2.3	0.1	4.1	2.3
Research and development	(29.6)	(23.4)	(87.4)	(68.2)
General and administrative	(15.6)	(17.0)	(45.7)	(59.9)
Marketing and sales	(29.5)	(34.1)	(88.3)	(99.7)
Other Operating Costs	(74.6)	(74.5)	(221.5)	(227.9)
Operating profit (loss)	29.9	15.8	26.3	19.6
Finance result (net) and share of result in associates	1.4	(3.1)	3.2	(11.6)
Profit (loss) before tax	31.2	12.7	29.5	8.0
Income tax credit (expense)	(8.8)	(5.2)	(10.7)	(10.8)
Profit (loss) for the period	22.4	7.5	18.9	(2.8)
Earnings per share
Basic, attributable to equity holders of the parent (US$)	0.032	0.011	0.027	(0.004)
Diluted, attributable to equity holders of the parent (US$)	0.030	0.010	0.025	(0.004)

Segment information – Revenues	3Q 2026	3Q 2025	9M 2026	9M 2025
Amounts in US$m
Revenue – RUCONEST (US)	94.0	81.1	224.2	227.4
Revenue – RUCONEST (EU and RoW)	(0.1)	1.1	0.3	3.9
Total Revenues – RUCONEST	93.8	82.2	224.5	231.2
Revenue – Joenja (US)	15.9	13.4	42.8	34.6
Revenue – Joenja (EU and RoW)	7.9	1.7	12.9	3.7
Total Revenues – Joenja	23.8	15.1	55.7	38.4
Total Revenues – US	109.8	94.5	267.0	262.0
Total Revenues – EU and RoW	7.7	2.7	13.2	7.6
Total Revenues	117.6	97.3	280.2	269.6

Consolidated Balance Sheet	September 30, 2026	December 31, 2025
Amounts in US$m
Cash and cash equivalents, restricted cash and marketable securities	190.9	181.1
Current assets	322.4	299.5
Total assets	496.6	500.0
Current liabilities	100.0	115.8
Shareholders’ equity	291.2	277.1

Figures may not add up due to rounding.

Financial highlights

Third quarter 2026

For the third quarter of 2026, total revenues increased by US$20.3 million, or 21%, to US$117.6 million, compared to US$97.3 million in the third quarter of 2025. RUCONEST revenues amounted to US$93.8 million, a 14% increase compared to the third quarter of 2025. This increase in RUCONEST revenues was primarily driven by a volume increase in the U.S. Joenja revenues amounted to US$23.8 million in the third quarter of 2026, a 58% increase compared to the third quarter of 2025. This increase in Joenja revenues was primarily driven by an increase in volume.

Gross profit increased by US$12.0 million or 13%, to US$102.2 million, compared to US$90.2 million in the third quarter of 2025, mainly due to the increase in revenues and partially offset by manufacturing-related impairments of inventory (US$5.1 million).

The operating profit increased 89% and amounted to US$29.9 million compared to US$15.8 million in the third quarter of 2025. Excluding US$5.1 million in one-time manufacturing-related impairments of inventory, adjusted operating profit¹ in the third quarter 2026 amounted to US$35.0 million. Excluding US$0.2 million of non-recurring Abliva acquisition-related expenses, adjusted operating profit in the third quarter 2025 amounted to US$16.0 million. The improved operating result was primarily driven by an increase in revenues and other income from government grants supporting research and development activities.

The finance result (net) and share of result in associates amounted to a gain of US$1.4 million compared to a loss of US$3.1 million in the third quarter of 2025. This improvement was mainly driven by favorable EUR/USD exchange rate movements, resulting in a foreign currency gain of US$2.6 million in 2026, compared to a loss of US$0.4 million in the third quarter of 2025.

The Company had a net profit of US$22.4 million, compared to a net profit of US$7.5 million in the third quarter of 2025. This increase was primarily driven by higher revenues and a favorable change in the net finance result.

Cash generated from operations amounted to US$32.4 million, broadly in line with US$32.0 million in the third quarter of 2025. Cash and cash equivalents, restricted cash and marketable securities increased by US$31.4 million from US$159.5 million at the end of the second quarter of 2026 to US$190.9 million at the end of the third quarter of 2026. This increase was primarily driven by net profit, partially offset by unfavorable working capital movements, including an increase in trade and other receivables.

¹ Adjusted Operating Profit is a non-IFRS measure used by management to assess underlying operating performance and provides additional insight into the Company’s core operating profitability. It excludes certain non-core items.

Nine months 2026

Total revenues increased 4% during the first nine months of 2026 to US$280.2 million, compared to US$269.6 million during the first nine months of 2025. Total RUCONEST revenues were 3% lower at US$224.5 million, compared to revenues of US$231.2 million for the first nine months of 2025. The decrease in RUCONEST revenues was primarily driven by a decrease in volume. Joenja revenues amounted to US$55.7 million in the first nine months of 2026, a 45% increase compared to the first nine months of 2025. This increase in Joenja revenues was primarily driven by an increase in volume.

Gross profit decreased by US$1.5 million, or 1%, to US$243.7 million, compared to US$245.2 million in the first nine months of 2025, mainly due to manufacturing-related impairments of inventory (US$10.0 million) partially offset by the increase in revenues.

The operating profit amounted to US$26.3 million compared to an operating profit of US$19.6 million in the first nine months of 2025. Excluding US$10.0 million in one-time manufacturing-related impairments of inventory and US$1.7 million in expenses associated with the closure of the production-support site in Évry, France, adjusted operating profit in the first nine months of 2026 amounted to US$38.0 million. Excluding US$10.1 million of non-recurring Abliva acquisition-related expenses, adjusted operating profit in the first nine months of 2025 amounted to US$29.7 million. The improved operating result was primarily driven by an increase in revenues and lower operating expenses, partially offset by manufacturing-related impairments of inventories in 2026.

The finance result (net) and share of result in associates amounted to a gain of US$3.2 million compared to a loss of US$11.6 million in the first nine months of 2025. This improvement was mainly driven by favorable EUR/USD exchange rate movements, resulting in a foreign currency gain of US$7.9 million in the first nine months of 2026, compared to a loss of US$5.0 million in the first nine months of 2025.

The Company had a net profit of US$18.9 million, compared to a net loss of US$2.8 million in the first nine months of 2025. This increase was primarily driven by higher revenues, lower operating expenses and a favorable change in the net finance result.

Cash generated from operations amounted to US$24.7 million, compared to US$44.0 million in the first nine months of 2025. Cash and cash equivalents, restricted cash and marketable securities increased by US$9.8 million from US$181.1 million at the end of 2025 to US$190.9 million at the end of the third quarter of 2026. This increase was primarily driven by net profit, partially offset by US$12.3 million settlement of the lease liability following the early termination of the DSP facility lease at Pivot Park in Oss, the Netherlands, in the first quarter of 2026.

Outlook/Summary

For 2026, the Company anticipates:

• Total revenues between US$380.0 million and US$390.0 million (1% to 4% growth).
• Total operating expenses between US$310.0 million and US$315.0 million (0% to 1% growth), including approximately US$35 million incremental R&D investment to advance the pipeline and US$9 million structural G&A cost reductions based on the plan announced in October 2025.
• RUCONEST revenue stabilization and return to growth during second half of 2026, and significant and accelerating annual Joenja U.S. and ex-U.S. growth.
• Commercial launches for leniolisib for APDS patients 12 years of age or older and for pediatrics in key global markets.
• Top-line data readouts for the two ongoing leniolisib Phase II clinical trials in PIDs with immune dysregulation, including CVID, to expand the asset’s addressable patient population.
• Continued progress in enrollment of the pivotal FALCON clinical study for napazimone (KL1333) in mitochondrial DNA-driven primary mitochondrial diseases, with completion of enrollment by the first half of 2027.
• Enhancing capital efficiency to drive growth and build a leading global rare disease company.
• Continued focus on potential acquisitions and in-licensing of clinical stage opportunities in rare diseases. Financing, if required, would come via a combination of our strong balance sheet and access to capital markets.

No further specific financial guidance for 2026 is provided.

Trademarks
Joenja® and RUCONEST® are registered trademarks owned by or licensed to Pharming Group N.V. or its affiliates.

Additional information
Presentation

The conference call presentation is available on the Pharming.com website from 07:30 CET today.

Conference Call

The conference call will begin at 13:30 CET/08:30 EDT on Tuesday, October 27. A transcript will be made available on the Pharming.com website in the days following the call.

Please note, the Company will only take questions from dial-in attendees.

Webcast Link:

https://edge.media-server.com/mmc/p/nnjperkk

Conference call dial-in details:

https://register-conf.media-server.com/register/BI6feabfc862ab4ba1bc7e6386d00414a3

Additional information on how to register for the conference call/webcast can be found on the Pharming.com website.

For further public information, contact:

Pharming
Michael Levitan, VP Investor Relations & Capital Markets
T: +1 (908) 705 1696
E: investor@pharming.com

Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com

Media Relations
Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming)
E: JDeutsch@lyraadvisory.com

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.

We combine specialized scientific, medical, regulatory and commercial expertise to advance a focused portfolio of approved medicines and development programs that address significant unmet medical needs. Guided by insights from patients and the wider rare disease community, we are dedicated to delivering innovative therapies for some of the most challenging rare diseases.

Pharming is headquartered in Leiden, the Netherlands, with operations in the United States and Europe.

For more information, visit www.pharming.com and find us on LinkedIn.

Auditor’s involvement
The Condensed Consolidated Interim Financial Statements have not been audited by the Company’s statutory auditor.

Forward-looking Statements

This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “goals”, “intend”, “may”, “milestones”, “objectives”, “outlook”, “plan”, “probably”, “project”, “risks”, “schedule”, “see”, “should”, “target”, “will” and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Pharming Group N.V.

Condensed Consolidated Interim Financial Statements in US Dollars (unaudited)

For the period ended September 30, 2026

• Condensed consolidated interim statement of income
• Condensed consolidated interim statement of comprehensive income
• Condensed consolidated interim balance sheet
• Condensed consolidated interim statement of changes in equity
• Condensed consolidated interim statement of cash flows

CONDENSED CONSOLIDATED INTERIM STATEMENT OF INCOME
For the period ended September 30
Amounts in US$ ‘000	9M 2026	9M 2025
Revenues	280,217	269,602
Costs of sales	(36,553)	(24,366)
Gross profit	243,664	245,236
Other income	4,097	2,303
Research and development	(87,389)	(68,221)
General and administrative	(45,738)	(59,945)
Marketing and sales	(88,345)	(99,746)
Other Operating Costs	(221,472)	(227,911)
Operating profit (loss)	26,289	19,628
Fair value gain (loss) on revaluation	—	—
Other finance income	11,152	1,748
Other finance expenses	(8,144)	(13,048)
Finance result, net	3,008	(11,300)
Share of net profits (loss) in associates using the equity method	233	(279)
Profit (loss) before tax	29,530	8,049
Income tax credit (expense)	(10,677)	(10,838)
Profit (loss) for the period	18,853	(2,790)
Attributable to:
Equity holders of the parent	18,853	(2,477)
Non-controlling interests	—	(313)
Earnings per share
Basic, attributable to equity holders of the parent (US$)	0.027	(0.004)
Diluted, attributable to equity holders of the parent (US$)	0.025	(0.004)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME
For the period ended September 30
Amounts in US$ ‘000	9M 2026	9M 2025
Profit (loss) for the period	18,853	(2,790)
Currency translation differences	(11,258)	26,092
Items that may be subsequently reclassified to profit or loss	(11,258)	26,092
Fair value remeasurement investments	—	—
Items that shall not be subsequently reclassified to profit or loss	—	—
Other comprehensive income (loss), net of tax	(11,258)	26,092
Total comprehensive income (loss) for the period	7,595	23,303
Attributable to:
Equity holders of the parent	7,595	23,616
Non-controlling interests	—	(313)

CONDENSED CONSOLIDATED INTERIM BALANCE SHEET
Amounts in US$ ‘000	September 30, 2026	December 31, 2025
Non-current assets
Intangible assets	125,667	135,538
Property, plant and equipment	6,165	7,233
Right-of-use assets	13,335	16,738
Long-term prepayments	91	94
Deferred tax assets	19,051	31,017
Investment accounted for using the equity method	2,109	1,944
Investment in debt instruments designated as at FVTPL	6,485	6,703
Restricted cash	1,355	1,227
Total non-current assets	174,258	200,495
Current assets
Inventories	57,988	64,902
Trade and other receivables	74,831	54,704
Restricted cash	—	761
Marketable securities	—	33,796
Cash and cash equivalents	189,560	145,305
Total current assets	322,379	299,469
Total assets	496,637	499,963
Equity
Share capital	8,086	8,009
Share premium	520,912	513,257
Other reserves	17,518	28,819
Accumulated deficit	(255,277)	(272,983)
Shareholders’ equity	291,239	277,102
Non-current liabilities
Convertible bonds	94,344	92,719
Lease liabilities	11,102	14,351
Total non-current liabilities	105,446	107,070
Current liabilities
Convertible bonds	5,584	5,336
Provisions	816	1,187
Trade and other payables	90,069	105,899
Lease liabilities	3,483	3,369
Total current liabilities	99,952	115,791
Total equity and liabilities	496,637	499,963

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY
For the period ended September 30
Attributable to owners of the parent
Amounts in US$ ‘000	Share capital	Share premium	Other reserves	Accumulated deficit	Total	Non-controlling interests	Total equity
Balance at January 1, 2025	7,769	488,990	(209)	(275,489)	221,061	—	221,061
Profit (loss) for the period	—	—	—	(2,477)	(2,477)	(313)	(2,790)
Reserves	—	—	—	—	—	—	—
Other comprehensive income (loss) for the period	—	—	26,092	—	26,092	—	26,092
Total comprehensive income (loss) for the period	—	—	26,092	(2,477)	23,616	(313)	23,303
Other reserves	—	—	(32)	32	—	—	—
Income tax benefit from excess tax deductions related to share-based payments	—	—	—	807	807	—	807
Share-based compensation	—	—	—	9,256	9,256	—	9,256
Options exercised / LTIP shares issued	184	18,727	—	(8,320)	10,592	—	10,592
Acquisition of a subsidiary	—	—	—	—	—	7,741	7,741
Acquisition of non-controlling interests	—	—	—	(687)	(687)	(7,428)	(8,115)
Total transactions with owners, recognized directly in equity	184	18,727	(32)	1,087	19,967	313	20,280
Balance at September 30, 2025	7,953	507,717	25,852	(276,878)	264,644	—	264,644
Balance at January 1, 2026	8,009	513,257	28,819	(272,983)	277,102	—	277,102
Profit (loss) for the period	—	—	—	18,853	18,853	—	18,853
Reserves	—	—	—	—	—	—	—
Other comprehensive income (loss) for the period	—	—	(11,258)	—	(11,258)	—	(11,258)
Total comprehensive income (loss) for the period	—	—	(11,258)	18,853	7,595	—	7,595
Other reserves	—	—	(43)	34	(9)	—	(9)
Income tax benefit from excess tax deductions related to share-based payments	—	—	—	(629)	(629)	—	(629)
Share-based compensation	—	—	—	8,353	8,353	—	8,353
Options exercised / LTIP shares issued	77	7,655	—	(8,905)	(1,173)	—	(1,173)
Total transactions with owners, recognized directly in equity	77	7,655	(43)	(1,147)	6,542	—	6,542
Balance at September 30, 2026	8,086	520,912	17,518	(255,277)	291,239	—	291,239

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS
For the period ended September 30
Amounts in $’000	9M 2026	9M 2025
Profit (loss) before tax	29,530	8,049
Adjustments to reconcile net profit (loss) to net cash used in operating activities:
Depreciation, amortization, impairment of non-current assets	8,745	8,010
Equity settled share based payments	8,353	9,256
Loss (gain) on disposal of leases	(2)	(9)
Impairments of inventories¹	11,777	2,183
Other finance income	(11,152)	(1,748)
Other finance expenses	8,088	12,837
Share of net result in associates using the equity method	(233)	279
Operating cash flows before changes in working capital	55,106	38,857
Changes in working capital:
Inventories¹	(5,372)	(5,686)
Provisions	(371)	—
Trade and other receivables	(14,801)	11,453
Payables and other current liabilities	(4,797)	4,138
Restricted cash	569	(1,018)
Total changes in working capital	(24,772)	8,887
Interest received	2,991	1,723
Income taxes received (paid)	(8,660)	(5,466)
Net cash flows generated from (used in) operating activities	24,665	44,001
Capital expenditure for property, plant and equipment	(601)	(480)
Investment intangible assets	—	(6)
Investment in associates using the equity method	—	(731)
Purchases of marketable securities	(102,646)	—
Proceeds from sale of marketable securities	18,124	84,990
Acquisition of a subsidiary, net of cash acquired	—	(57,476)
Net cash flows generated from (used in) investing activities	(85,123)	26,297
Payment of lease liabilities	(14,803)	(2,877)
Interests on lease liabilities	(349)	(848)
Interests on convertible bonds	(2,614)	(2,506)
Settlement of share based compensation awards	5,703	14,564
Acquisition of non-controlling interests	—	(7,876)
Net cash flows generated from (used in) financing activities	(12,063)	457
Increase (decrease) of cash	(72,521)	70,755
Exchange rate effects	(1,020)	6,672
Effect of reclassification of money market funds to cash and cash equivalents2	117,796	—
Cash and cash equivalents at the beginning of the period	145,305	54,944
Total cash and cash equivalents at September 30	189,560	132,370

---

¹ Comparative presentation updated for consistency.
² Money market funds are classified as cash equivalents from April 1, 2026

Attachment

• Pharming Group reports third quarter 2026 results_EN_27OCT2026

News Summary:

• NVIDIA and Meta will expand their partnership on Muse and the Muse family of models, reflecting popular demand for AI agents.
• The companies are also considering other technological collaborations, including NVIDIA OpenShell Reference Architecture to strengthen agency security and NVIDIA Sentry for monitoring, structured, unstructured and graph data processing.
• Meta to expand NVIDIA Vera Rubin and Vera CPU deployment to boost performance and scale workloads with NVIDIA Spectrum-X Ethernet networking and BlueField-4.

SANTA CLARA, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) — NVIDIA and Meta today announced they will partner to expand their work on Muse and the Muse family of models to improve inference and training performance, reflecting popular demand for useful AI agents.

Meta’s Muse models and agents, which leverage NVIDIA’s infrastructure, have delivered frontier-level benchmark performance and surging consumer downloads since launch. Meta and NVIDIA intend to further deepen their collaboration by partnering on optimizations across workflows to maximize performance and improve total cost of ownership. Meta and NVIDIA will also consider additional collaboration opportunities with NVIDIA on its NVIDIA OpenShell Reference Architecture, including NVIDIA OpenShell™ for safe deployment and NVIDIA Sentry for monitoring agent behavior.

This announcement reinforces Meta and NVIDIA’s strong long-term partnership to support Meta’s AI infrastructure ambitions. Meta intends to expand the deployment of NVIDIA infrastructure, including Vera Rubin and Vera CPUs for next-generation AI agents to deliver maximum performance per watt. Meta will also deploy NVIDIA Spectrum-X™ Ethernet networking and BlueField-4^® to support network efficiency and throughput.

In addition, NVIDIA will invest $3 billion in Meta’s equity offering.

“AI agents represent a new computing paradigm — software that understands our goals, reasons, uses tools and gets work done on our behalf,” said Jensen Huang, founder and CEO of NVIDIA. “This changes how we use computers, from operating applications to working with intelligent agents. NVIDIA and Meta are expanding our partnership to optimize the computing infrastructure end to end for capable, efficient and secure AI agents, so Muse can empower billions of people to achieve more and pursue greater ambitions.”

“Muse is how we bring personal superintelligence to everyone. We’re excited to keep working with NVIDIA to deliver the best personal agents and frontier models for billions of people,” said Mark Zuckerberg, founder and CEO of Meta.

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:
Mylene Mangalindan
Corporate Communications
NVIDIA Corporation
press@nvidia.com 

Toshiya Hari
Investor Relations
NVIDIA Corporation
ir@nvidia.com

NVIDIA Forward-Looking Statements
Certain statements in this press release including, but not limited to, statements as to: expectations with respect to NVIDIA’s proposed investment in Meta, including its anticipated completion and any applicable closing conditions; expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments, and related trends and drivers; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on NVIDIA’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, and other NVIDIA product and service names are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries and regions. Other company, product, and service names may be trademarks of the respective companies with which they are associated.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/915679a6-3b0b-41f7-8fac-5f6958b3ae3e

Mowi ASA hereby invites you to the presentation of the results for the third quarter 2026 at The Salmon, Strandpromenaden 11, 0252 Oslo, Norway.

The results will be presented in English through a live webcast followed by a Q&A session. Participants will have the opportunity to submit questions online throughout the webcast session. The webcast will be available on http://www.mowi.com/investors/reports/

A recording of the webcast will be made available on our website immediately afterwards.

Please note that the quarterly report and presentation will be published at 06:30 (CET).

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Lawson 5 near the western edge of the Prairie Evaporite has confirmed an active, generative Natural Hydrogen system in a 30-km step-out from the first four wells within the Lawson Complex near Central Butte in south-central Saskatchewan. Drilling at Lawson 6 is now in progress 8 km to the southeast. 

Concurrent with continued discovery-focused drilling, MAX Power has commenced its completions program beginning with the Bracken target in the southwest corner of the province to be followed shortly by the start of comprehensive testing at Lawson in an attempt to confirm the world’s first large-scale commercial discovery of a new primary energy source.

Video: The Next Chapter
https://youtu.be/LUIHqS35rMg

REGINA, Saskatchewan, Oct. 27, 2026 (GLOBE NEWSWIRE) —  MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FSE: 89N) (“MAX Power” or the “Company”) is pleased to report that drilling at “Lawson 5”, a 30-km step-out from the original Lawson Natural Hydrogen Discovery near Central Butte, Saskatchewan, has confirmed the presence of a Natural Hydrogen system along the western edge of the Prairie Evaporite, and a follow-up well (Lawson 6) is now in progress approximately 8 km southeast of this new discovery.

The scale of the Natural Hydrogen opportunity in Saskatchewan is highlighted in part by the fact that MAX Power has now confirmed active, generative Natural Hydrogen systems in three distinct areas separated by as much as 365 kilometers across the central and southern part of the province, from the western edge of the Prairie Evaporite southwest through the Lawson Complex (Lawson 1 to 4) to the Bracken target in the far southwest near the Montana border. A completions program has also just commenced at Bracken and crews will head north next week to begin testing the Lawson Complex for flow, concentrations, and volume as MAX Power’s commercial validation program intensifies.

Highlights

• Lawson 5 was successfully cased after being drilled to a total depth of 2,175 meters and will form part of the upcoming Lawson completions program (62 meters of core recovered for analysis);
• The lowermost Deadwood and Precambrian basement complex at Lawson 5 features much more pronounced iron redox, alteration and serpentinization reactions than observed to date at Lawson, including strong hematite oxidation, associated with elevated levels of Natural Hydrogen along sub-vertical faults within a package of exotic terrane source rocks;
• The Lower Interlake, above the Deadwood Formation, features helium prospective zones that will be examined for potential testing during completions.

Mr. Steve Halabura, MAX Power Chief Geoscientist, commented: “MAX Power’s pioneering work in Natural Hydrogen continues to excite and amaze our geological team. Whether we’ve hit an entirely separate Natural Hydrogen system at L-5, or whether this is connected to the Lawson Complex, will be determined through more drilling and geophysical work we’ll be undertaking to optimize our understanding of the local and regional faulting and fracture systems. Lawson 5 skirted the edge of the Salt Wall. Lawson 6 to the southeast has a greater probability of drilling right through the Prairie Evaporite.”  

Mr. Halabura added: “At the Lawson Complex we are continuing to review copious amounts of data ahead of the near-term start of completions. It has become increasingly apparent that at Lawson 4, we hit the Natural Hydrogen ‘kitchen’, but a kitchen that is potentially even bigger and more robust than originally believed. We look forward to providing an update on Lawson 4 and the broader Lawson Complex shortly.”

Mr. Rob Norris, MAX Power CEO, commented: “This further expansion of the Natural Hydrogen opportunity in Saskatchewan speaks to both the favorable geology in this resource-rich province and the dedication and skill of our entire team. We’re excited to see what Lawson 6 brings as we also commence the completions round beginning at Bracken, something we’ve been eagerly anticipating for months. All of this is occurring as we approach the start of the world’s largest Natural Hydrogen conference (H-NAT) in Paris, France, where I’ll be joined next week by several of our team members as MAX Power is a significant sponsor of this event.”

Figure 1 – Lawson 5 Drill Core Sample

Figure 2 – Lawson 5 Drill Core Sample

Why This Matters to Investors

MAX Power’s latest results are reinforcing a much larger geological opportunity than a single Natural Hydrogen discovery. With active, generative systems now identified at the Lawson Complex and in significant step-outs at Lawson 5 (next to the Prairie Evaporite) and at Bracken in the southwest corner of the province, an area spanning 365 kilometers, the Company is building evidence for the potential of Natural Hydrogen deposits across a basin-scale exploration corridor. Importantly, these geographically separated discoveries support the broader exploration thesis while providing additional targets for technical evaluation.

The commencement of completions at Bracken, followed immediately by comprehensive testing at Lawson, represents a critical next step. MAX Power is moving beyond confirming the presence of Natural Hydrogen toward measuring the characteristics that will determine its commercial potential: Natural Hydrogen concentrations, sustained flow rates, reservoir pressures, connectivity and ultimately recoverable volumes and production economics. The aggressive, back-to-back program is designed to generate important technical data across multiple targets while drilling continues to investigate the potential for new discoveries.

At the same time, MAX Power is advancing the broader commercial strategy required to potentially bring a new primary energy source to market. Alongside its technical program, the Company continues to evaluate infrastructure requirements, prospective energy markets and opportunities for future commercial development. This parallel approach reflects MAX Power’s “Months to Molecules” strategy: Advancing geological discovery, commercial validation and potential routes to market together, rather than sequentially.

For investors, the significance is the convergence of these developments. MAX Power is expanding its understanding of the regional Natural Hydrogen opportunity while beginning the testing needed to establish whether that geological potential can translate into commercially viable energy production.

Figure 3 – MAX Power Drilling at Lawson 5 Well (October 2026)

MAX Power Attends Two Prominent Investor Conferences This Week

MAX Power is pleased to announce its participation in two prominent investor conferences taking place in Toronto on Wednesday and Thursday, October 28 and 29, 2026. Chad Levesque, President and Director, will present at the Planet MicroCap Showcase: Toronto 2026, powered by MicroCapClub, on Wednesday, October 28, at 12:00 p.m. Eastern Time, at Arcadian Court & Loft, 401 Bay Street.

The conference brings together leading microcap investors, emerging growth companies and industry professionals for corporate presentations and one-on-one investor meetings. Rob Norris, CEO and Director, will present at the Red Cloud Fall Mining Showcase on Wednesday, October 28, at 1:40 p.m. Eastern Time, at the Omni King Edward Hotel, 37 King Street East. The Red Cloud Showcase brings together mining and exploration companies, institutional investors and resource-sector professionals.

In addition to their presentations, Mr. Levesque and Mr. Norris will conduct dozens of one-on-one investor meetings throughout the two conferences, engaging directly with institutional investors, fund managers and other members of the investment community. These meetings will provide an opportunity to discuss MAX Power’s recent advancements at its Lawson Natural Hydrogen Discovery, the Company’s ongoing exploration and testing programs, and its broader strategy to advance the commercialization of Natural Hydrogen across Saskatchewan’s Genesis Trend. The Company’s participation in both conferences reflects its continued commitment to expanding investor awareness, strengthening relationships within the capital markets and positioning MAX Power at the forefront of the emerging Natural Hydrogen sector.

Figure 4 – Genesis Trend Map – 475 km “Natural Hydrogen Highway”

MAX Power Raises $1.66 Million Through Warrant & Option Exercises

MAX Power is pleased to report that from September 1 through October 15, 2026, the Company further solidified its strong cash position by raising a total of $1,662,000 through the exercise of warrants (1,187,500 warrants for $1,462,500) and stock options (891,667 for $199,500).

Hampton Agreement

Effective October 13, 2026, MAX Power entered into an advisory fee agreement (the “Agreement”) with Hampton Securities Limited (“Hampton”), pursuant to which Hampton will provide advisory services to the Company. The engagement period commences on the date the Agreement was executed and extends until December 31, 2026.

In consideration for the advisory services, the Company has agreed to pay Hampton a one-time advisory fee of $400,000 plus applicable taxes, payable upon execution of the Agreement. The Agreement is non-exclusive, and Hampton is not entitled to any compensation other than the advisory fee.

Hampton is located at 141 Adelaide Street West, Suite 1800, Toronto, Ontario, M5H 3L5. Its primary contact is Andrew Deeb, Managing Director – Investment Banking (Telephone: 416-862-8686; Email: adeeb@hamptonsecurities.com).
 
Any securities of the Company held by Hampton were not received as compensation for the advisory services under the Agreement, and no securities of the Company are issuable to Hampton under the Agreement.

Amended Marketing Agreement – RazorPitch

MAX Power has further amended its investor marketing and consulting agreement (the “Agreement”) with RazorPitch, Inc. (“RazorPitch”), previously announced by the Company, to continue and expand the scope of services and increase the compensation payable thereunder.

Under two amendments, effective October 5, 2026, and October 13, 2026, respectively, RazorPitch will continue to provide investor awareness marketing services, including digital, social, influencer and broker marketing, together with news amplification services, in addition to the services previously disclosed under the Agreement.

In consideration for the additional services, the Company will pay RazorPitch additional cash fees of $250,000 USD under each amendment, for an aggregate additional fee of $500,000 USD, bringing total cash consideration payable to RazorPitch under the Agreement, as amended, to $850,000 USD. No securities of the Company are issuable to RazorPitch as compensation under the Agreement, as amended.

The term of the Agreement is unchanged and continues until November 14, 2026. All other terms of the Agreement remain unchanged. To the knowledge of the Company, RazorPitch and its principals remain at arm’s length to the Company and do not hold any securities of the Company. RazorPitch is responsible for ensuring that its promotional activities comply with applicable securities laws and CSE policies.

Marketing Agreement – EMC

MAX Power has engaged Emerging Markets Consulting, LLC (“EMC”) to conduct an influencer and AI discoverability campaign (the “Campaign”) to raise awareness of Natural Hydrogen and the Company for a 2-week period beginning the week of October 26, 2026. In consideration for the Campaign, the Company has agreed to pay EMC $200,000 USD. EMC is located at 390 North Orange Avenue, Suite 2300, Orlando, Florida, and its principal is James S. Painter. EMC deals with the Company at arm’s length, and neither EMC nor its principals own, directly or indirectly, any securities of the Company. EMC’s compensation is payable in cash only, not securities of the Company.

Stay Connected by Following Us On

X (formerly Twitter): x.com/MaxPowerMining
LinkedIn: linkedin.com/company/max-power-mining-corp
Instagram: instagram.com/maxpowerminingcorp
YouTube: youtube.com/@maxpowerminingcorp
and by joining our Telegram channel: t.me/MaxpowerMining

Recent Videos

Video: The Time is Now
https://youtu.be/TKnEnBEQ0TM

What if the Answer to Natural Hydrogen Was Beneath Our Feet All Along?
https://youtu.be/srV-RCmzzPk

President Chad Levesque On Significance of Lawson
https://youtu.be/wCeFQTKtOuI

What is Natural Hydrogen?
https://www.youtube.com/watch?v=S0bqqZeIpxc

Genesis Explained: Its “Salt Barrier” Advantage and Proximity to Demand
https://www.youtube.com/watch?v=3ytpHdve6S8

The Genesis Trend’s Industrial Corridor
https://youtube.com/shorts/IAgALH_s3mI

Lawson – Canada’s First Big Step into Natural Hydrogen
https://www.youtube.com/watch?v=lTTOwMxz_zo

MAX Power Leaps at Lawson
https://www.youtube.com/watch?v=Yr4Ha06__Eg

Watch the Drill in Action
https://www.youtube.com/watch?v=eguNGAfdIek

MAX Power Saskatchewan Natural Hydrogen Documentary Video
https://www.youtube.com/watch?v=TXGDtTUbJ2c

History in The Making at Lawson – Video Immediately Ahead of Drill Rig Setup
https://www.youtube.com/watch?v=BNHazk9Sy4E

About MAX Power

MAX Power is an innovative mineral and energy exploration company focused on the shift to decarbonization. The Company’s Lawson Discovery near Central Butte, Saskatchewan, represents Canada’s first-ever subsurface Natural Hydrogen system confirmed through deep drilling with data validated by three independent labs. MAX Power has built dominant district-scale land positions across Saskatchewan with approximately 2.5 million acres (~1 million hectares) of permits covering prime exploration ground prospective for large-volume accumulations of Natural Hydrogen, and has commenced a multi-well follow-up drill program to validate the commerciality of the broader Lawson Complex interpreted to cover a 28 sq. km area along the 475-km Genesis Trend. MAX Power also holds a significant equity position in Homeland Critical Minerals, which now owns the Willcox Project in Arizona, a lithium discovery confirmed in early 2024 by MAX Power. MAX Power is committed to responsible exploration and development practices that prioritize environmental stewardship, meaningful community engagement, and strong corporate governance.

On behalf of the Board of Directors,

Rob Norris, CEO
MAX Power Mining Corp.
info@maxpowermining.com

For further information, please contact:

Chad Levesque, President
Ph: 1-306-981-4753
chad@maxpowermining.com

Media Contact:

Sarah Mawji, Venture Strategies
sarah@venturestrategies.com

Cautionary Statement and Forward-Looking Information

This news release contains certain forward-looking statements and forward-looking information (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is often identified by words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “should”, “will” and similar expressions.

Forward-looking information is based on management’s current expectations, estimates, projections and assumptions, including, among other things, that required regulatory approvals will be obtained, financing will be available on acceptable terms, planned exploration, appraisal and development activities will proceed as anticipated, equipment and personnel will be available as required, geological interpretations and technical results will support further advancement of the Company’s projects, and market conditions will remain favourable.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, without limitation, risks relating to exploration and development activities, geological and technical uncertainties, commercialization of Natural Hydrogen, reservoir performance, infrastructure availability, strategic partnership opportunities, market acceptance, commodity and energy prices, access to capital, regulatory approvals, environmental and permitting requirements, and general economic, market and business conditions.

There can be no assurance that the Company’s plans, expectations or objectives will be achieved. Readers are cautioned not to place undue reliance on forward-looking information. Forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update or revise any forward-looking information, whether due to new information, future events or otherwise, except as required by applicable securities laws.

Additional information regarding the Company and the risks and uncertainties affecting its business and operations is available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3c587228-2c54-48d2-88cf-62702349ca82

https://www.globenewswire.com/NewsRoom/AttachmentNg/eda1ee8a-1e16-45d6-a934-d2de321d56eb

https://www.globenewswire.com/NewsRoom/AttachmentNg/664f07bb-6a5d-4f35-a8f3-fd8c173305bb

https://www.globenewswire.com/NewsRoom/AttachmentNg/b3e47607-9409-4d33-9649-b1e18043e034

https://www.globenewswire.com/NewsRoom/AttachmentNg/e600d3cd-9999-4ca4-be56-bfb5d492869e

This press release was published by a CLEAR® Verified individual.

 Senior appointment strengthens UAE corporate and international tax leadership to help clients navigate complex corporate and international tax requirements

DUBAI, United Arab Emirates, Oct. 27, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Sandeep Kumar as a Senior Managing Director in the Tax practice within the firm’s Corporate Finance segment, reflecting increasing client demand for practical UAE corporate tax, international tax and technology-enabled compliance support.

Mr. Kumar, who is based in Dubai, will help listed companies, multinationals and family-owned groups navigate UAE corporate tax and international tax matters by providing practical advice across structuring, cross-border transactions, compliance, engagement with the tax authority and technology-enabled transformation of the tax function.

“Sandeep’s appointment marks an important next step in the growth of our Tax practice in the Middle East,” said Nilesh Ashar, a Senior Managing Director and Head of Middle East Tax at FTI Consulting. “Since the introduction of UAE corporate tax, Sandeep has worked with businesses across the full lifecycle, from initial impact assessment and implementation through compliance, clarifications and tax return filings. His combination of technical expertise, sector knowledge and experience developing technology-enabled solutions will add meaningful value for clients as they respond to a rapidly evolving regional tax environment.”

Mr. Kumar brings 17 years of corporate and international tax experience, with approximately a decade of it in the GCC. He has advised clients across the oil and gas, utilities, real estate, education, retail and consumer sectors, and has represented clients before the tax authority, supported complex private clarification requests and assisted in developing tax technology solutions to improve corporate tax compliance.

“Sandeep’s experience will strengthen the connectivity between our regional Tax team and our wider EMEA capabilities,” said Euan Sutherland, Head of EMEA Tax at FTI Consulting. “His understanding of UAE corporate tax, international tax and technology-enabled compliance will be valuable to organisations managing increasingly complex obligations across jurisdictions in the region. He also brings a strong commitment to developing people and sharing technical knowledge, which will support the continued growth of our team.”

Prior to joining FTI Consulting, Mr. Kumar was a partner at a leading tax advisory firm in the UAE, where he built and led the corporate tax team and headed its learning and development and thought leadership programme. He previously held senior tax roles in the Big Four accounting firms in the UAE, India and Oman. Mr. Kumar is a Chartered Accountant (ICAI) and holds the IBFD Advanced Professional Certificate in International Taxation (APCIT).

Commenting on his appointment, Mr. Kumar said, “UAE corporate tax has moved quickly from implementation to a phase of closer scrutiny, and businesses now need advice that combines technical depth with practical, commercially grounded solutions. I look forward to working with Nilesh and expert colleagues across the region, Corporate Finance and EMEA to build a UAE corporate tax practice that clients rely on for exactly that, and to develop the next generation of tax talent along the way.”

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organisations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalised and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.  
200 Aldersgate
Aldersgate Street
London, EC1A 4HD

Investor Contact:  
Mollie Hawkes 
+1.617.747.1791 
mollie.hawkes@fticonsulting.com 

Media Contact:  
publicrelations@fticonsulting.com

SYDNEY, Oct. 26, 2026 (GLOBE NEWSWIRE) — Omni Bridgeway Limited (ASX: OBL), a leading global alternative asset manager specialising in legal assets, has released its Investment Portfolio Report as at 30 September 2026 (1Q27). The first quarter of the financial year (FY27) delivered elevated completion returns, 24% growth in management fees and the final close of Funds 4/5 Series II at its full US$1 billion target, with the Group tracking at or above all of its FY27 operational targets.

Key Highlights

1. Strong completion returns: 20 full and partial completions generated A$135.8 million in investment proceeds at a 3.9x multiple on invested capital (MOIC), well above the two-year trailing average of 2.5x, and a fair value conversion ratio of 102%.
2. Growing fee income: Management fees of A$10.7 million were up 24% on 1Q26. Cash carried interest of A$9.4 million was received during the quarter, with a further approximately A$8.6 million accrued on Series II funds and not yet distributed.
3. Funds 4/5 Series II closed at US$1 billion: The final close of the Series II raise was achieved at the full US$1 billion target, which is expected to accelerate management fee growth towards the higher end of the range indicated for FY27.
4. Commitments and an elevated pipeline: New commitments of A$87.1million were made to nine new investments, up 23% on 1Q26 and in line with normal seasonality, adding A$81.2 million in new fair value. The pipeline now comprises 46 agreed exclusive term sheets representing an estimated A$416.6 million in new commitments if contracted, up from A$317.8 million at 1Q26.
5. Measured cost management: Cash operating expenses of A$15.7 million are tracking below the FY27 budget range of A$72.5–75.0 million, with a cost coverage ratio of 68% for the quarter.

Managing Director and Chief Executive Officer Raymond van Hulst commented:

“Omni Bridgeway has made a strong start to FY27. Completions delivered a 3.9x multiple, management fees grew 24% and the final close of Series II at US$1 billion on improved terms underpins further fee growth.

With 46 exclusive term sheets and a significant number of late-stage investments in the portfolio, we remain well positioned for the rest of the year.”

Outlook and Upcoming Dates

Favourable market and competitive dynamics continue to support a strong pipeline with appropriate risk-adjusted pricing. Management fee growth is expected to accelerate following the Series II final close, while cash operating expenses are expected to increase in later quarters, in line with the FY27 budget.

Omni Bridgeway’s Annual General Meeting will be held today, 27 October 2026. The 2Q27 Investment Portfolio Report is expected to be released on 29 January 2027. The full 1Q27 Investment Portfolio Report is available via the ASX announcements platform.

Investor and Media Contacts

Media

Naomi Barber, Director, Business Development & Marketing
+61 421 371 844, nbarber@omnibridgeway.com

Investor Relations

Nathan Kandapper, Global Head of Investor Relations
+61 403 941 502, nkandapper@omnibridgeway.com

ABOUT OMNI BRIDGEWAY

Omni Bridgeway is the world’s leading alternative asset manager dedicated to legal finance, with over A$5.9 billion in assets under management across multiple funds. Founded in 1986 and listed on the ASX since 2001, Omni Bridgeway has pioneered the industry and has a unique track record of consistent outperformance across multiple decades and economic cycles. With a team of approximately 160 professionals operating in over 20 locations and 15 countries, Omni Bridgeway is the largest and most diversified institutional platform for primary origination, underwriting and management of legal assets and risk, across all relevant jurisdictions and areas of law.

CARY, N.C., Oct. 26, 2026 (GLOBE NEWSWIRE) — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, November 9, 2026, at 8:30 a.m. ET to report third quarter financial results and discuss recent business highlights.

The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400

CHIHUAHUA, Mexico, Oct. 26, 2026 (GLOBE NEWSWIRE) — Grupo Bafar, S.A.B. de C.V. (BIVA: BAFARB) (“Grupo Bafar” or the “Company”), a leading Mexico-based food company, today announced its financial results for the third quarter ended September 30, 2026. The Company reported year-over-year growth, supported by ongoing innovation, digital transformation and expansion initiatives.

Third Quarter 2026 Highlights

• Net sales were Ps. 8,889.6 million, up 11.5% year over year.
• Operating income was Ps. 1,208.4 million, representing an operating margin of 13.6%.
• EBITDA was Ps. 1,559.4 million, up 24.3% year over year.
• Net income was Ps. 675.3 million, representing a net margin of 7.6%.

Grupo Bafar delivered record third-quarter sales and improved profitability, driven by higher sales volumes, a greater contribution from higher-value-added businesses and disciplined operating cost management.

Bafar Alimentos, the Company’s food division, reported third-quarter net sales of Ps. 8,367.6 million, an increase of 9.8% YoY, supported by performance across its sales channels. The Company continued to expand its company-operated retail footprint to capture additional value, enhance operating margins and drive profitable long-term growth.

The food division reported EBITDA of Ps. 1,149.3 million, an increase of 18.6% year over year, with an EBITDA margin of 13.7%. Capital expenditures (CapEx) totaled Ps. 1,124 million, primarily reflecting investments in the expansion of the commercial network, the expansion of distribution centers in Chihuahua (Ps. 646 million) and construction of a new regional distribution center in Villahermosa. The Company expects these initiatives to enhance supply chain efficiency and support long-term value creation.

Fibra Nova reported total revenue of Ps. 441.2 million, an increase of 12.5% year over year, supported by 100% occupancy and contributions from new leases. EBITDA totaled Ps. 479.6 million, equivalent to 108.7% of revenue, compared with 100.3% in the prior-year period. Quarterly investments totaled Ps. 326.9 million, primarily allocated to build-to-suit industrial developments. Fibra Nova ended the quarter with a loan-to-value (LTV) ratio of 31%.

Grupo Bafar’s Financial Division reported credit and factoring originations of Ps. 1,314.9 million, reflecting increased demand from small and medium-sized enterprises (SMEs) and strategic suppliers. Quarterly revenue rose 22.3% YoY to Ps. 313.7 million. Operating income totaled Ps. 96.1 million, while EBITDA reached Ps. 97.6 million. The number of active B-Cash cards exceeded 1,117, an increase of 86.2% YoY.

The Company’s real estate division continued to advance Valle de los Encinos, its flagship development in Chihuahua. Residential lot sales generated revenue of Ps. 237.4 million during the quarter. Hotel del Valle de los Encinos also commenced operations and is expected to contribute progressively to recurring revenue, alongside the development’s restaurant and hospitality offerings.

Looking ahead, Grupo Bafar plans to advance its commercial expansion, brand development and operational automation initiatives. Management expects these investments to enhance efficiency, support margin resilience and strengthen the Company’s competitive position.

“The strength of our operations and the continued progress of our automation and infrastructure projects demonstrate Grupo Bafar’s ability to execute. Each strategic initiative we undertake is guided by a clear focus on efficiency and scalability. We believe we have the financial strength, talent and operational discipline to pursue new opportunities, deliver profitable growth and build long-term value for our shareholders,” said Eugenio Baeza, Chief Executive Officer of Grupo Bafar.

About Grupo Bafar

Headquartered in Chihuahua, Mexico, Grupo Bafar, S.A.B. de C.V. operates businesses spanning food production and distribution, financial services, real estate development and industrial real estate through Fibra Nova. The Company’s shares are listed on the Bolsa Institucional de Valores (BIVA) under the ticker symbol BAFARB.

Investor Relations Contact:

Luis Carlos Piñón Reza

lpinon@bafar.com.mx

ir@bafar.com.mx

https://ri.bafar.investorcloud3.net/